DAFNA Capital Management’s Allogene Therapeutics ALLO Stock Holding History

DAFNA Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16M	Buy	2,000,000 +629,882	+46%	+$1.38M	0.79%	29
2026 Q1	$3.34M	Sell	1,370,118 -10,000	-0.7%	-$20K	0.76%	35
2025 Q4	$1.89M	Hold	1,380,118	–	–	0.44%	51
2025 Q3	$1.71M	Hold	1,380,118	–	–	0.42%	48
2025 Q2	$1.56M	Hold	1,380,118	–	–	0.43%	44
2025 Q1	$2.01M	Buy	1,380,118 +140,000	+11%	+$264K	0.57%	38
2024 Q4	$2.64M	Buy	1,240,118 +190,000	+18%	+$469K	0.67%	33
2024 Q3	$2.94M	Buy	1,050,118 +445,018	+74%	+$1.19M	0.69%	36
2024 Q2	$1.41M	Buy	+605,100	New	+$1.79M	0.34%	51

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

DAFNA Capital Management's ALLO Position: Q2 2026 in Review

DAFNA Capital Management increased its Allogene Therapeutics (ALLO) stake by 46% in Q2 2026, buying an estimated $1.38M and bringing the position to 2,000,000 shares worth $4.16M. The position accounts for 0.79% of the portfolio, ranked #29.

DAFNA Capital Management first reported a position in ALLO in Q2 2024 and has held it in 9 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

DAFNA Capital Management held 2,000,000 shares of Allogene Therapeutics worth $4.16M as of Q2 2026.
DAFNA Capital Management bought 629,882 Allogene Therapeutics shares in Q2 2026, an estimated $1.38M.
Allogene Therapeutics made up 0.79% of DAFNA Capital Management's portfolio in Q2 2026, its #29 holding.
DAFNA Capital Management first reported a position in Allogene Therapeutics in Q2 2024 and has held it in 9 quarters since.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.